Kuros Biosciences AG Stock Swiss Exchange
Equities
CH0325814116
Biotechnology & Medical Research
Sales 2022 | 17.99M 19.67M 26.88M | Sales 2023 | 33.56M 36.7M 50.16M | Capitalization | 128M 140M 192M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.31M -20.92M | Net income 2023 | -13M -14.21M -19.43M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.15M 33.01M | Net cash position 2023 | 12M 13.12M 17.93M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.71% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |